Genomic loss of heterozygosity and survival in the REAL3 trial

BACKGROUND: Homologous recombination deficiency (HRD) measured using a genomic signature for loss of heterozygosity (LOH) predicts benefit from rucaparib in ovarian cancer. We hypothesized that some oesophagogastric cancers will have high-LOH which would be prognostic in patients treated with platin...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Smyth, Elizabeth C., Cafferkey, Catherine, Loehr, Andrea, Waddell, Tom, Begum, Ruwaida, Peckitt, Clare, Harding, Thomas C., Nguyen, Minh, Okines, Alicia F., Raponi, Mitch, Rao, Sheela, Watkins, David, Starling, Naureen, Middleton, Gary W., Wadsley, Jonathan, Mansoor, Wasat, Crosby, Tom, Wotherspoon, Andrew, Chau, Ian, Cunningham, David
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2018
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6291175/
https://ncbi.nlm.nih.gov/pubmed/30613349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26336
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak